GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » EPS without NRI

AVITA Medical (AVITA Medical) EPS without NRI : $-1.40 (TTM As of Dec. 2023)


View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical EPS without NRI?

AVITA Medical's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-0.28. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 12.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for AVITA Medical's EPS without NRI or its related term are showing as below:

RCEL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.8   Med: 12   Max: 72.4
Current: 12.2

During the past 13 years, AVITA Medical's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 72.40% per year. The lowest was -78.80% per year. And the median was 12.00% per year.

RCEL's 3-Year EPS without NRI Growth Rate is ranked better than
55.26% of 704 companies
in the Medical Devices & Instruments industry
Industry Median: 8.95 vs RCEL: 12.20

AVITA Medical's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.28. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40.

AVITA Medical's EPS (Basic) for the three months ended in Dec. 2023 was $-0.28. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.40.


AVITA Medical EPS without NRI Historical Data

The historical data trend for AVITA Medical's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVITA Medical EPS without NRI Chart

AVITA Medical Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.56 -2.07 -1.17 -1.07 -1.40

AVITA Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.37 -0.41 -0.34 -0.28

Competitive Comparison of AVITA Medical's EPS without NRI

For the Medical Devices subindustry, AVITA Medical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVITA Medical's PE Ratio without NRI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AVITA Medical's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where AVITA Medical's PE Ratio without NRI falls into.



AVITA Medical EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AVITA Medical  (NAS:RCEL) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


AVITA Medical EPS without NRI Related Terms

Thank you for viewing the detailed overview of AVITA Medical's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


AVITA Medical (AVITA Medical) Business Description

Address
28159 Avenue Stanford, Suite 220, Valencia, Los Angeles, CA, USA, 91355
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the U.S. with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 U.S. burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the U.S. region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the U.S.
Executives
James Corbett director 2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook director TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
David D O'toole officer: CFO 1640 MARENGO STREET, LOS ANGELES CA 90033
Donna Shiroma officer: General Counsel C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance director 800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Robert Mcnamara director C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
Michael S Perry director, officer: Chief Executive Officer C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Suzanne Crowe director C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Jan Stern Reed director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder officer: Chief Financial Officer 6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee officer: Chief Operating Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins officer: Sr. VP of Finance C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre officer: Chief Financial Officer SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Damien Mcdonald director 5 MERCHANT SQUARE, NORTH WHARF ROAD, LONDON X0 W21AY
Erin Liberto officer: Chief Commercial Officer C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355

AVITA Medical (AVITA Medical) Headlines